<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Recurrent pregnancy loss: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Recurrent pregnancy loss: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Recurrent pregnancy loss: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Togas Tulandi, MD, MHCM, FRCSC, FACOG, FCAHS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Haya M Al-Fozan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen Eckler, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-quality data on management of recurrent pregnancy loss (RPL) are limited; therefore, therapeutic recommendations are largely based upon clinical experience and data from observational studies. Nevertheless, the prognosis for a successful future pregnancy is generally good: The overall live birth rates after normal and abnormal diagnostic evaluations for RPL are 77 and 71 percent, respectively [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         In all cases, emotional support is important in caring for these often anxious couples, and may enhance therapeutic success [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Management of RPL will be discussed here. Causes and evaluation of RPL are reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5437.html" rel="external">
          "Recurrent pregnancy loss: Definition and etiology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5436.html" rel="external">
          "Recurrent pregnancy loss: Evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.
        </p>
        <p class="headingAnchor" id="H2325533552">
         <span class="h1">
          CAUSES OF RPL AND TARGETED TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients in whom a likely cause for RPL is identified undergo treatment targeted to that problem.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Parental karyotype abnormality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Couples in whom chromosomal abnormalities are discovered in one or both partners or the abortus are generally referred for genetic counseling [
         <a href="#rid3">
          3
         </a>
         ]. They should receive information regarding the probability of having a chromosomally normal or abnormal conception in the future. In the latter case, the risk of miscarriage and bearing a chromosomally abnormal offspring who may be phenotypically normal or abnormal and a carrier of a chromosomal defect should be discussed. The magnitude of these risks varies according to the specific chromosomal abnormality and the sex of the carrier parent. (See
         <a class="medical medical_review" href="/z/d/html/4490.html" rel="external">
          "Chromosomal translocations, deletions, and inversions"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/452.html" rel="external">
          "Congenital cytogenetic abnormalities"
         </a>
         .)
        </p>
        <p>
         Couples with karyotypic abnormalities may choose to undergo prenatal genetic studies, such as amniocentesis or chorionic villus sampling, to determine the fetal karyotype. Pregnancy termination is an option if the fetus is affected. In vitro fertilization (IVF) with preimplantation genetic testing (PGT) can be used to avoid transfer and implantation of an affected embryo [
         <a href="#rid4">
          4,5
         </a>
         ]. PGT improves the pregnancy outcome of translocation carriers with a history of repeated pregnancy loss [
         <a href="#rid6">
          6
         </a>
         ]. On the other hand, this procedure reduces the live birth rate after IVF if preimplantation testing is performed solely because of advanced maternal age [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">
          "Preimplantation genetic testing"
         </a>
         .)
        </p>
        <p>
         Gamete donation (egg or sperm), surrogacy, and adoption are methods of preventing conception of an affected embryo. The choice depends upon the specific abnormality and parental preference. (Refer to individual topic reviews on these topics).
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Uterine abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine abnormalities are managed surgically if the defect is a surgically correctable cause of pregnancy loss, such as a uterine septum, intrauterine adhesions, or submucosal myoma. These conditions can be treated hysteroscopically. (See
         <a class="medical medical_review" href="/z/d/html/3292.html" rel="external">
          "Congenital uterine anomalies: Surgical repair"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3285.html" rel="external">
          "Intrauterine adhesions: Clinical manifestation and diagnosis"
         </a>
         .)
        </p>
        <p>
         There are no randomized trials evaluating pregnancy outcome after surgical correction of uterine anomalies. In a classic observational series, repair of bicornuate and septate uteri reduced the abortion rate from 84 percent (before surgery) to 12 percent (after surgery) [
         <a href="#rid8">
          8
         </a>
         ]. The problem with this and similar studies is use of patients as their own controls [
         <a href="#rid9">
          9
         </a>
         ]. However, studies using better control groups also support the efficacy of surgical correction of uterine defects, especially for uterine septum.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective study, the probability of conception and live birth in women after hysteroscopic metroplasty was significantly higher than in women with unexplained infertility (live birth rate 34.1 versus 18.9 percent) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study, the effect of uterine septum on IVF outcome was investigated in 289 embryo transfers before and 538 embryo transfers after hysteroscopic resection of uterine septum and in a control group that underwent two consecutive embryo transfers [
         <a href="#rid11">
          11
         </a>
         ]. For women with a large septum, the live birth rate was 2.7 percent before surgery and 15.6 percent after surgery versus 20.9 percent in the control group. For women with a small septum, the live birth rate was 2.8 percent before surgery and 18.6 percent after surgery versus 21.9 percent in the control group.
        </p>
        <p>
        </p>
        <p>
         The value of prophylactic cervical cerclage in women with a uterine anomaly, but no history of second-trimester pregnancy loss, is controversial [
         <a href="#rid12">
          12
         </a>
         ]. We do not advocate prophylactic cervical cerclage in women with no history of cervical insufficiency. (See
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6737.html" rel="external">
          "Transvaginal cervical cerclage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6739.html" rel="external">
          "Transabdominal and laparoscopic cervicoisthmic cerclage"
         </a>
         .)
        </p>
        <p>
         A gestational carrier is an option for women with irreparable uterine defects. (See
         <a class="medical medical_review" href="/z/d/html/7431.html" rel="external">
          "Gestational carrier pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Antiphospholipid syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drugs such as
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and heparin appear to improve pregnancy outcome in women with antiphospholipid syndrome who have recurrent fetal losses. In contrast, such therapy is not associated with improved outcomes in women without antiphospholipid antibody syndrome. (See
         <a class="medical medical_review" href="/z/d/html/6813.html" rel="external">
          "Antiphospholipid syndrome: Obstetric implications and management in pregnancy"
         </a>
         and
         <a class="local">
          'Aspirin with or without heparin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Thyroid dysfunction and diabetes mellitus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with overt thyroid disease or diabetes mellitus should be treated, as medically appropriate, since these disorders can result in serious sequelae. (See
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7872.html" rel="external">
          "Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">
          "Subclinical hypothyroidism in nonpregnant adults"
         </a>
         .)
        </p>
        <p>
         Women with elevated serum thyroid peroxidase antibody concentrations are at high risk of developing hypothyroidism in the first trimester and autoimmune thyroiditis postpartum, and should be followed appropriately [
         <a href="#rid13">
          13
         </a>
         ]. Euthyroid women with high serum thyroid peroxidase antibody concentrations may benefit from treatment with thyroid hormone during pregnancy as this therapy may reduce the risk of miscarriage and preterm birth [
         <a href="#rid14">
          14
         </a>
         ]. In a randomized trial, administration of
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         (median dose 50 mcg daily) to early pregnant euthyroid women with positive thyroid peroxidase antibodies decreased the miscarriage rate from 13.8 to 3.5 percent (relative risk [RR] 1.72, 95% CI 1.13-2.25) [
         <a href="#rid15">
          15
         </a>
         ]. In addition, the incidence of premature deliveries in treated women was lower than in those who were not treated (7.0 versus 22.4 percent, RR 1.66, 95% CI 1.18-2.34). A limitation of this study is that the mean gestational age of starting therapy was 10 weeks, and all but one of the losses had occurred at less than 11 weeks. Further study is required to evaluate the efficacy of levothyroxine in women with RPL and positive thyroid peroxidase antibodies. (See
         <a class="medical medical_review" href="/z/d/html/7851.html" rel="external">
          "Overview of thyroid disease and pregnancy", section on 'Thyroid peroxidase antibodies in euthyroid women'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Hyperprolactinemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Normal circulating levels of prolactin may play an important role in maintaining early pregnancy. A study of 64 hyperprolactinemic women with RPL randomly assigned to
         <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">
          bromocriptine
         </a>
         therapy or no bromocriptine found treatment was associated with a significantly higher rate of successful pregnancy (86 versus 52 percent) [
         <a href="#rid16">
          16
         </a>
         ]. Prolactin levels during early pregnancy were significantly greater in women who miscarried. We suggest treatment of women with hyperprolactinemia and RPL, even in the absence of overt hypogonadism. (See
         <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">
          "Management of hyperprolactinemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1458294561">
         <span class="h1">
          DIAGNOSES NOT ASSOCIATED WITH RPL
         </span>
        </p>
        <p class="headingAnchor" id="H1159654983">
         <span class="h2">
          Polycystic ovary syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The miscarriage rate in women with polycystic ovary syndrome (PCOS) is 20 to 40 percent, higher than the baseline rate in the general obstetric population [
         <a href="#rid17">
          17
         </a>
         ].
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         has been used in women with PCOS to decrease this risk, but the effectiveness of this approach is unproven. (See
         <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">
          "Metformin for treatment of the polycystic ovary syndrome", section on 'Spontaneous abortion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3907474009">
         <span class="h2">
          Suspected immunologic dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although no alloimmune mechanism has been proven to cause RPL, several immunologic treatments have been advocated to improve the live birth rate in women with previous unexplained RPL. None are effective, and some appear to be harmful [
         <a href="#rid18">
          18-20
         </a>
         ]. (See
         <a class="local">
          'Immune therapy with intravenous immunoglobulin'
         </a>
         below and
         <a class="local">
          'Glucocorticoids'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Thrombophilia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anticoagulation of women with certain inherited thrombophilias may improve maternal outcome (eg, prevention of venous thromboembolism), but does not appear to prevent pregnancy loss. These issues are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">
          "Inherited thrombophilias in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          TREATMENT OPTIONS FOR UNEXPLAINED RECURRENT PREGNANCY LOSS
         </span>
         <span class="headingEndMark">
          —
         </span>
         After evaluation, RPL remains unexplained in approximately one-half of couples. Nevertheless, the chance of a live birth is good (ie, over 50 percent with no intervention). This rate must be considered in evaluating therapies for unexplained RPL.
        </p>
        <p>
         Although data may be lacking, treatments that may be offered to couples with unexplained RPL include the following:
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Lifestyle modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiological studies suggest that lifestyle modifications can increase fertility potential, although these have not been definitively tested in randomized trials. These modifications include eliminating use of tobacco products, alcohol, and caffeine and reduction in body mass index (for obese women). (See
         <a class="medical medical_review" href="/z/d/html/5411.html" rel="external">
          "Natural fertility and impact of lifestyle factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Human menopausal gonadotropin
         </span>
         <span class="headingEndMark">
          —
         </span>
         An observational study reported that controlled ovarian stimulation via human menopausal gonadotropin (hMG) administration appeared effective for treatment of endometrial defects in women with RPL [
         <a href="#rid21">
          21
         </a>
         ]. The mechanism may be correction of a luteal phase defect or stimulation of a thicker endometrium, thus leading to a better implantation site. Our clinical experience supports the efficacy of this treatment, although not all societies support its use [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          In vitro fertilization and preimplantation genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies evaluating the value of in vitro fertilization (IVF) in women with RPL have yielded mixed results [
         <a href="#rid23">
          23
         </a>
         ]. Embryos of women with unexplained RPL have a higher incidence of aneuploidy for chromosomes 13,16,18, 21, 22, X, and Y than embryos obtained from healthy women [
         <a href="#rid24">
          24
         </a>
         ]. In a retrospective cohort study of 300 women with RPL, the pregnancy, live birth, and miscarriage rates were similar for women who underwent IVF with preimplantation screening (PGS) and women who elected expectant management [
         <a href="#rid23">
          23
         </a>
         ]. Of the 168 retrievals performed 38 cycles (23 percent) were cancelled because of poor embryo yield or quality. Of the 130 completed PGS cycles, 103 (74 percent) yielded at least one euploid embryo. (See
         <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">
          "Preimplantation genetic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Oocyte donation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Poor quality oocytes may be responsible for 25 percent of pregnancy losses [
         <a href="#rid25">
          25
         </a>
         ]. Ovum donation can overcome this problem and has been associated with a live birth rate of 88 percent in women with RPL [
         <a href="#rid25">
          25
         </a>
         ]. The success of ovum donation, even when the male partner's sperm is utilized for fertilization, suggests the absence of a significant paternal contribution to the etiology of RPL. (See
         <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">
          "In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H78195586">
         <span class="h2">
          Gestational carrier
         </span>
         <span class="headingEndMark">
          —
         </span>
         A gestational carrier may be considered by women with RPL or recurrent IVF implantation failures not associated with recurrent embryonic aneuploidy or obvious intrinsic gamete factors (eg, single gene defects, diminished oocyte and embryo quality). Women who decide to pursue this route should undergo a thorough evaluation as to the etiology of the RPL or failed IVF. (See
         <a class="medical medical_review" href="/z/d/html/7431.html" rel="external">
          "Gestational carrier pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H78195290">
         <span class="h1">
          INEFFECTIVE OR UNPROVEN THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following therapies are not supported by data, and we do not recommend them.
        </p>
        <p class="headingAnchor" id="H3948472676">
         <span class="h2">
          Progesterone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supplemental vaginal
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         therapy in women with repeated pregnancy loss does not appear to increase the live birth rate, including for patients with RPL, and therefore we do not use it [
         <a href="#rid26">
          26-28
         </a>
         ]. However, we recognize that there is not universal agreement for this approach [
         <a href="#rid29">
          29
         </a>
         ]. For example, the National Institute for Health Care and Excellence (NICE) advises offering vaginal micronized progesterone to individuals who have experienced one or more prior pregnancy losses and have bleeding early in the current pregnancy (progesterone is not advised for individuals with early pregnancy bleeding who have not experienced a prior loss nor for individuals with a history of prior loss who do not have bleeding in early pregnancy) [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
         Our rationale is informed by the following data:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trials in patients with history of RPL
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Trial with only RPL patients
         </strong>
         – In the largest trial, which included over 800 women with RPL randomly assigned to first-trimester vaginal
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         therapy or placebo, approximately two-thirds of women in each group delivered a live infant after 24 weeks of gestation (progesterone and placebo birth rates: 66 versus 63 percent) [
         <a href="#rid32">
          32
         </a>
         ]. Furthermore, there were no differences between the groups in the rates of clinical pregnancy at six to eight weeks, ongoing pregnancy at 12 weeks, ectopic pregnancy, miscarriage, or stillbirth. There were also no differences in neonatal outcomes. For this study, RPL was defined as three or more first-trimester pregnancy losses.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Trial with mixed population
         </strong>
         – A trial comparing
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         400 mg vaginal suppository with placebo in pregnant patients experiencing vaginal bleeding before 10 weeks gestational age reported similar live birth rates among patients with one, two, or three or more prior pregnancy losses and those receiving placebo (live birth rates of 78, 93, and 73 percent compared with 84 percent, respectively) [
         <a href="#rid28">
          28
         </a>
         ]. The trial was stopped at the interim analysis, after having enrolled 278 of 386 planned participants, for lack of effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subgroup analysis of trial data
         </strong>
         – A subgroup analysis of a subsequent trial reported, for women with three or more prior pregnancy losses, an increased live birth rate following vaginal
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         treatment compared with placebo (72 versus 57 percent, relative rate 1.28, 95% CI 1.08-1.51), but the results were based on a prespecified study subgroup limited to 285 women total [
         <a href="#rid33">
          33
         </a>
         ]. In this trial, the live birth rates reflected delivery at 34 weeks gestation or greater.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Network meta-analysis
         </strong>
         – In a pre-specified subgroup analysis of pregnant individuals with one or more prior pregnancy losses and early pregnancy bleeding (ie, threatened miscarriage), a small increase in live birth rate was reported for those treated with vaginal micronized
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         compared with placebo (relative risk 1.08, 95% CI 1.02-1.14, test for subgroup differences p = 0.02) [
         <a href="#rid31">
          31
         </a>
         ]. No improvement was reported for patients without prior pregnancy loss who were experiencing early pregnancy bleeding or for those with a history of recurrent pregnancy loss but no active bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In response to this network meta-analysis, NICE guideline NG126 recommends the use of vaginal micronized
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         in patients with vaginal bleeding (ie, threatened miscarriage) and a history of one or more pregnancy losses [
         <a href="#rid30">
          30,34
         </a>
         ]. Vaginal micronized progesterone 400 mg is inserted twice daily. It is particularly effective in those with confirmed fetal heartbeat. However, it is ineffective in patients with no previous miscarriages and early pregnancy bleeding.
        </p>
        <p>
        </p>
        <p>
         It is not known if treatment with intramuscular
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         or other progestins would improve the live birth rate in women with RPL. Additionally, as the therapeutic effect of progesterone may be related to immune modulation, it is possible that earlier initiation of progesterone, such as during the luteal phase, may improve outcome [
         <a href="#rid35">
          35
         </a>
         ]. As an example, in a small study of women with RPL (defined as two or more unexplained pregnancy losses &lt;10 weeks of gestation), luteal phase treatment with micronized progesterone improved the 10-week pregnancy rate for the subgroup with elevated nCyclinE expression (&gt;20 percent), compared with their prior pregnancy success (69 versus 6 percent). Live birth rates were not reported. However, as benefit was seen in only one subgroup of women in a small study, we do not prescribe luteal phase micronized progesterone in women with RPL.
        </p>
        <p class="headingAnchor" id="H78195333">
         <span class="h2">
          Aspirin with or without heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trials have reported that neither
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         [
         <a href="#rid36">
          36,37
         </a>
         ] nor aspirin plus anticoagulants improve the live birth rate of women with unexplained RPL [
         <a href="#rid38">
          38-40
         </a>
         ]. Data specific to individuals with RPL include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a trial comparing
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">
          nadroparin
         </a>
         , 364 women with unexplained RPL were randomly assigned to receive daily aspirin (80 mg), aspirin plus nadroparin (2850 international units), or placebo. Aspirin or placebo was begun preconceptionally and nadroparin was started as soon as a viable pregnancy was documented by ultrasound. Among the 299 women who became pregnant, the live-birth rates for combination therapy, aspirin alone, and placebo were not significantly different: 69, 62, and 67 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another trial randomly assigned 294 women with ≥2 consecutive unexplained pregnancy losses at ≤24 weeks to treatment with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         and low dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or no treatment; both groups received intensive pregnancy surveillance [
         <a href="#rid39">
          39
         </a>
         ]. Medical therapy did not reduce the rate of pregnancy loss, which was 22 percent with drug treatment and 20 percent without it.
        </p>
        <p>
        </p>
        <p>
         While a post hoc per-protocol analysis of a multicenter trial reported that, compared with placebo, low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         initiated prior to conception and continued throughout pregnancy was associated with fewer pregnancy losses, the study population had experienced one to two prior losses and not RPL [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H78195367">
         <span class="h2">
          Low-molecular weight heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low-molecular weight heparin (LMWH) is frequently offered to patients with unexplained recurrent miscarriage, although no benefit has been reported for patients with or without an inherited thrombophilia [
         <a href="#rid40">
          40,42-45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with thrombophilia
         </strong>
         – An open label randomized trial comparing low-dose LMWH with standard care in patients aged 18 to 42 years with two or more pregnancy losses and confirmed inherited thrombophilia reported similar live birth rates between the groups (72 and 71 percent, respectively, absolute risk difference 0.7 percent, 95% CI -9.2 to 10.6) [
         <a href="#rid45">
          45
         </a>
         ]. Additional discussion of pregnancy in patients with inherited thrombophilias is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">
          "Inherited thrombophilias in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients without thrombophilia
         </strong>
         – One double-blind trial randomly assigned 258 pregnant women who had a history of unexplained RPL (two or more consecutive miscarriages before 15 weeks gestation) and a negative thrombophilia work-up to either subcutaneous daily LMWH (
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         40 mg) or placebo [
         <a href="#rid42">
          42
         </a>
         ]. Enoxaparin treatment did not improve the chance of a live birth. In another trial of 449 women with RPL and no thrombophilia, there were no differences in live birth rates between women randomly assigned to
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         5000 international units daily versus placebo (86 and 87 percent) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H78195469">
         <span class="h2">
          Human chorionic gonadotropin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Human chorionic gonadotropin (hCG) therapy during early gestation may be useful in preventing miscarriage since endogenous hCG is known to play a critical role in the establishment of pregnancy. A systematic review of four trials involving 180 women with RPL found hCG therapy was associated with a significantly reduced risk of miscarriage (odds ratio [OR] 0.26, 95% CI 0.14-0.52), particularly in women with oligomenorrhea [
         <a href="#rid46">
          46
         </a>
         ]. However, there were important methodological weaknesses in two of these studies. To date, there is insufficient evidence to recommend the use of hCG to prevent pregnancy loss in women with a history of unexplained RPL. Large randomized controlled trials are needed.
        </p>
        <p class="headingAnchor" id="H78195528">
         <span class="h2">
          Clomiphene citrate
         </span>
         <span class="headingEndMark">
          —
         </span>
         By increasing serum FSH,
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate increases follicular number and serum estradiol levels, which should lead to an increase in the number of corpora lutea and a higher midluteal
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         concentration [
         <a href="#rid47">
          47
         </a>
         ]. Two randomized trials comparing clomiphene with progesterone for treatment of inadequate luteal phase demonstrated similar pregnancy rates (20 to 30 percent) with each treatment [
         <a href="#rid48">
          48
         </a>
         ]. Clomiphene, unlike progesterone, does not prolong the luteal phase, thereby lessening the anxiety and period of uncertainty of infertile couples concerning possible conception. Due to the anti-estrogen effect of clomiphene on the endometrium, we do not use clomiphene in women with RPL.
        </p>
        <p class="headingAnchor" id="H1446563906">
         <span class="h2">
          Immune therapy with intravenous immunoglobulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systematic reviews have consistently found no beneficial effect of immunotherapy for treatment of RPL [
         <a href="#rid18">
          18,19,49,50
         </a>
         ]. The general findings are illustrated by the following two examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A systematic review of 20 trials of high quality showed that immunotherapy did not result in a statistically significant improvement in live births compared with untreated controls [
         <a href="#rid18">
          18
         </a>
         ]. Four types of immunotherapy were evaluated: paternal cell immunization (OR 1.23, 95% CI 0.89-1.70; 12 studies including 641 participants); third party donor cell immunization (OR 1.39, 95% CI 0.68-2.82; three studies including 156 participants); trophoblast membrane infusion (OR 0.40, 95% CI 0.11-1.45; one study including 37 participants); and intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (OR 0.98, 95% CI 0.61-1.58; eight studies including 303 participants).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another systematic review evaluated three randomized and two cohort trials of immunotherapy treatment specifically in patients who failed IVF; a total of 373 patients were involved in these trials [
         <a href="#rid49">
          49
         </a>
         ]. Patients treated with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         showed a consistently higher live birth rate than untreated controls; this benefit was statistically significant when the trial results were pooled in meta-analysis. However, there were many differences among these trials, such as the preparations used, the timing of the intervention (preconception, postconception, both), and dose, as well as the immunological abnormalities of the patients. In addition, some controls received heparin and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         while others did not receive any therapy. Thus, appropriate use of this therapy remains unclear.
        </p>
        <p>
        </p>
        <p>
         Immune therapy of RPL should be considered experimental, and used only in the setting of a clinical trial regulated by an Institutional Review Board.
        </p>
        <p class="headingAnchor" id="H1446564037">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids have several anti-inflammatory effects, including suppression of natural killer cell activity, but do not appear to be effective for preventing RPL. This was illustrated by a trial in which 202 women with RPL and a variety of autoantibodies (antinuclear, anti-DNA, antilymphocyte, anticardiolipin, lupus anticoagulant) were randomly assigned to receive either
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (0.5 to 0.8 mg per kilogram of body weight per day) and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (100 mg per day) or placebo for the duration of the pregnancy. The two groups did not have a statistically significant difference in rate of live birth (66 and 56 percent, respectively).
        </p>
        <p>
         Oral administration of glucocorticoids for treatment of RPL has been abandoned because of uncertain efficacy and a clearly demonstrable increase in complications, such as preterm premature rupture of membranes, gestational diabetes, and maternal hypertension. Alternative methods of glucocorticoid treatment, which are under investigation, may be safer.
        </p>
        <p class="headingAnchor" id="H1336814820">
         <span class="h2">
          Other medications and/or combinations
         </span>
         <span class="headingEndMark">
          —
         </span>
         While medications that impact endometrial development and immune function have showed initial promise, there are inadequate data to support their use. Combined treatment with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , and folate does not appear to be beneficial.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          Sitagliptin
         </a>
         – A study that evaluated the impact of sitagliptin, an inhibitor of dipeptidyl-peptidase IV, reported improved endometrial mesenchymal stem-like progenitor cell (eMSC) colony counts in the endometrium for patients treated with sitagliptin compared with placebo [
         <a href="#rid51">
          51
         </a>
         ]. Reduced eMSC colony counts have been associated with impaired decidualization [
         <a href="#rid52">
          52,53
         </a>
         ]. However, the study was small and did not assess the clinically important outcomes of pregnancy or live birth rates. While sitagliptin may be a promising future treatment, adequately powered clinical trial data are needed before this drug is prescribed for routine clinical use in patients with RPL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Granulocyte colony stimulating factor (G-CSF)
         </strong>
         – Preliminary studies have supported a possible role for use of recombinant human G-CSF in patients with RPL [
         <a href="#rid54">
          54
         </a>
         ]. Similar to
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         above, the pilot study for G-CSF was small and did not assess the clinically important outcomes of pregnancy or live birth rates. Adequately powered clinical trial data are needed before this drug is prescribed for routine clinical use in patients with RPL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combined medical therapy
         </strong>
         – An observational study compared 50 pregnant women who were treated before and during pregnancy with a combination of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (20 mg/day),
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         (20 mg/day),
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (100 mg/day), and folate (5 mg every second day) with 52 women who were not treated during the same observation period [
         <a href="#rid55">
          55
         </a>
         ]. The first-trimester miscarriage rate was 19 percent in the treated group and 63 percent in the control group; this difference was not statistically significant. The live birth rates in the treated group and control groups were 77 and 35 percent, respectively (p = 0.04). With combined treatment of four agents, it is unclear which of the treatments was beneficial. The nonrandomized design and small number of cases also limit the usefulness of this study.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H26414623">
         <span class="h2">
          Continued pregnancy loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         The greatest risk of recurrent loss occurs during the period up to the time of previous miscarriage.
        </p>
        <p>
         The likelihood of successful pregnancy in women with a history of RPL was evaluated in a single center cohort study of 987 women [
         <a href="#rid56">
          56
         </a>
         ]. At five years after the initial visit to a tertiary care center for RPL, 67 percent of women had a live birth. Increasing maternal age and a higher number of miscarriages at time of initial visit were associated with a significant decrease in the likelihood of having a live birth. Another study of women with unexplained RPL showed that 167 of 222 women who conceived subsequently had a successful pregnancy beyond 24 weeks of gestation (75 percent) [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         In women with recurrent early first-trimester pregnancy loss, the presence of fetal cardiac activity is reassuring of subsequent viable delivery, although the pregnancy loss rate remains above that of the general population. A literature review of studies examining fetal loss rates after sonographic demonstration of fetal cardiac activity reported the rate of such losses in women with RPL was 5 to 22 percent compared with 7 to 15 percent in infertile populations and 3 to 6 percent in controls [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Second-trimester pregnancy loss is significantly associated with recurrent second-trimester loss and future spontaneous preterm birth. After a second-trimester pregnancy loss, one study reported 39 percent of women had a preterm delivery in their next pregnancy, 5 percent had a stillbirth, and 6 percent had a neonatal death [
         <a href="#rid59">
          59
         </a>
         ]. In another study of 30 women with second-trimester loss, the frequency of recurrent second-trimester loss was 27 percent and the frequency of subsequent preterm birth was 33 percent [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26414616">
         <span class="h2">
          Other obstetric issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with a history of RPL who become pregnant may be at higher risk for developing fetal growth restriction and premature delivery, but not for gestational hypertension or diabetes.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preterm birth and perinatal death
         </strong>
         – A meta-analysis of 18 studies comparing over 68,000 individuals with a history of unexplained RPL with nearly 2.5 million control females reported twice the risk of preterm birth in those with a history of RPL (pooled odds ratio [OR] 2.05, 95% CI 1.46-2.89) [
         <a href="#rid61">
          61
         </a>
         ]. A dose-dependent effect was noted with risk of preterm birth risk increasing with rising number of prior pregnancy losses. An earlier retrospective cohort study that compared 2030 individuals with RPL to over 28,000 control females also reported an increased incidence of preterm birth (8 versus 5.5 percent) as well as increased incidence of very preterm birth &lt;32 weeks gestation (2.2 versus 1.2 percent) and perinatal death (1.2 versus 0.5 percent) for those with RPL [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fetal growth restriction
         </strong>
         – A different study that compared 162 women with RPL to control women additionally reported increased rates of fetal growth restriction (13 versus 2 percent) and cesarean delivery (36 versus 17 percent) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Obstetric management depends upon the underlying cause of RPL, if known.
        </p>
        <p class="headingAnchor" id="H1886066753">
         <span class="h2">
          Marker of future maternal health
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies have evaluated reproductive events as markers for future maternal illness or premature death [
         <a href="#rid64">
          64-66
         </a>
         ]. A study that utilized self-reported questionnaire data collected every two years from nurses reported an association between recurrent spontaneous abortion and death before the age of 70 years (hazard ratio 1.59, 95% CI 1.17-2.15 for three or more spontaneous pregnancy losses) [
         <a href="#rid67">
          67
         </a>
         ]. While these findings raise interesting clinical associations, more study is required to clarify the impact of reproductive events on future maternal health.
        </p>
        <p class="headingAnchor" id="H2526512668">
         <span class="h1">
          RESOURCES FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Ffaqs%2Frepeated-miscarriages%3Futm_source%3Dhigher-logic%26utm_medium%3Demail%26utm_content%3Djan-25%26utm_campaign%3Dacog2023-digest&amp;token=V2okwtOJYd6RPlhjvFa5asXcwkPk87%2F2G%2Fr%2FyR71Fb%2ByX6TliDmcUHh4ZSQTJ7UKOjtMZjaRzaE9deThjsAM906V%2BQ6hPmmPFwNgbtMPiEHgGUP%2FTZA39f5W3aGFpdcI%2FuffEga3SKKJRTOdAfWxkheNfsvnjq6pgjZpbP7XGqQ%3D&amp;TOPIC_ID=5444" target="_blank">
          Frequently Asked Questions
         </a>
         page for patients is available online through the American College of Obstetricians and Gynecologists.
        </p>
        <p class="headingAnchor" id="H2842571168">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114520.html" rel="external">
          "Society guideline links: Recurrent pregnancy loss"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15051229">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/85800.html" rel="external">
          "Patient education: Repeat pregnancy loss (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/139726.html" rel="external">
          "Patient education: Coping after pregnancy loss (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2714916517">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/132376.html" rel="external">
          "Patient perspective: Pregnancy loss"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chromosomal anomalies
         </strong>
         – Couples in whom chromosomal abnormalities are discovered in one or both partners or the abortus are generally referred for genetic counseling, which should include information about the probability of having a chromosomally normal or abnormal conception, and options for managing this risk. (See
         <a class="local">
          'Parental karyotype abnormality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uterine abnormalities
         </strong>
         – Uterine abnormalities are managed surgically if the defect is a surgically correctable cause of pregnancy loss, such as a uterine septum, intrauterine adhesions, or submucosal myoma. These conditions can be treated hysteroscopically. (See
         <a class="local">
          'Uterine abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment options
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Identified etiology
         </strong>
         – When a likely cause is identified for the patient's RPL, that problem is treated as indicated. This includes surgical correction of uterine anomalies and medical therapy for endocrine disorders such as hyperprolactinemia, thyroid abnormalities, and diabetes mellitus. (See
         <a class="local">
          'Causes of RPL and targeted treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Unexplained RPL
         </strong>
         – A variety of treatments have been offered to couples with unexplained RPL. We start with low risk, simple, and less expensive interventions and, if unsuccessful, move on to higher risk, more complex and expensive options. (See
         <a class="local">
          'Treatment options for unexplained recurrent pregnancy loss'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For most patients with the unexplained RPL, we suggest against using supplemental vaginal
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). The use of vaginal progesterone once a pregnancy has been established does not appear to improve live birth rates. However, some clinicians may reasonably offer vaginal progesterone in high-risk pregnancies, particularly in those with a history of recurrent pregnancy loss and early bleeding, as there may be a modest benefit in this subgroup. (See
         <a class="local">
          'Progesterone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For individuals with RPL, we recommend
         <strong>
          not
         </strong>
         using immunotherapy (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ) or glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). These drugs are not effective and may be harmful. (See
         <a class="local">
          'Immune therapy with intravenous immunoglobulin'
         </a>
         above and
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obstetric prognosis
         </strong>
         – Women with a history of RPL who become pregnant may be at higher risk for developing fetal growth restriction and premature delivery. Detection of fetal cardiac activity in early pregnancy is reassuring of subsequent viable delivery, although the pregnancy loss rate remains above that of the general population. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Harger JH, Archer DF, Marchese SG, et al. Etiology of recurrent pregnancy losses and outcome of subsequent pregnancies. Obstet Gynecol 1983; 62:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997; 12:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurino MY, Bennett RL, Saraiya DS, et al. Genetic evaluation and counseling of couples with recurrent miscarriage: recommendations of the National Society of Genetic Counselors. J Genet Couns 2005; 14:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munné S, Cohen J, Sable D. Preimplantation genetic diagnosis for advanced maternal age and other indications. Fertil Steril 2002; 78:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werlin L, Rodi I, DeCherney A, et al. Preimplantation genetic diagnosis as both a therapeutic and diagnostic tool in assisted reproductive technology. Fertil Steril 2003; 80:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otani T, Roche M, Mizuike M, et al. Preimplantation genetic diagnosis significantly improves the pregnancy outcome of translocation carriers with a history of recurrent miscarriage and unsuccessful pregnancies. Reprod Biomed Online 2006; 13:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mastenbroek S, Twisk M, van Echten-Arends J, et al. In vitro fertilization with preimplantation genetic screening. N Engl J Med 2007; 357:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinonen PK, Saarikoski S, Pystynen P. Reproductive performance of women with uterine anomalies. An evaluation of 182 cases. Acta Obstet Gynecol Scand 1982; 61:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patton PE, Novy MJ, Lee DM, Hickok LR. The diagnosis and reproductive outcome after surgical treatment of the complete septate uterus, duplicated cervix and vaginal septum. Am J Obstet Gynecol 2004; 190:1669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mollo A, De Franciscis P, Colacurci N, et al. Hysteroscopic resection of the septum improves the pregnancy rate of women with unexplained infertility: a prospective controlled trial. Fertil Steril 2009; 91:2628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomaževič T, Ban-Frangež H, Virant-Klun I, et al. Septate, subseptate and arcuate uterus decrease pregnancy and live birth rates in IVF/ICSI. Reprod Biomed Online 2010; 21:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ansari AH, Kirkpatrick B. Recurrent pregnancy loss. An update. J Reprod Med 1998; 43:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marqusee E, Hill JA, Mandel SJ. Thyroiditis after pregnancy loss. J Clin Endocrinol Metab 1997; 82:2455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bliddal S, Feldt-Rasmussen U, Rasmussen ÅK, et al. Thyroid Peroxidase Antibodies and Prospective Live Birth Rate: A Cohort Study of Women with Recurrent Pregnancy Loss. Thyroid 2019; 29:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negro R, Formoso G, Mangieri T, et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 2006; 91:2587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirahara F, Andoh N, Sawai K, et al. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril 1998; 70:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17:2858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong LF, Porter TF, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2014; :CD000112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutton B, Sharma R, Fergusson D, et al. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG 2007; 114:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christiansen OB, Larsen EC, Egerup P, et al. Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial. BJOG 2015; 122:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li TC, Ding SH, Anstie B, et al. Use of human menopausal gonadotropins in the treatment of endometrial defects associated with recurrent miscarriage: preliminary report. Fertil Steril 2001; 75:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ESHRE Guideline Group on RPL, Bender Atik R, Christiansen OB, et al. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open 2018; 2018:hoy004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murugappan G, Shahine LK, Perfetto CO, et al. Intent to treat analysis of in vitro fertilization and preimplantation genetic screening versus expectant management in patients with recurrent pregnancy loss. Hum Reprod 2016; 31:1668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassold TJ. A cytogenetic study of repeated spontaneous abortions. Am J Hum Genet 1980; 32:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remohí J, Gallardo E, Levy M, et al. Oocyte donation in women with recurrent pregnancy loss. Hum Reprod 1996; 11:2048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Practice Committees of the American Society for Reproductive Medicine and the Society for Reproductive Endocrinology and Infertility. Diagnosis and treatment of luteal phase deficiency: a committee opinion. Fertil Steril 2021; 115:1416.
          </a>
         </li>
         <li class="breakAll">
          Recurrent pregnancy loss. European Society of Human Reproduction and Embryology. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx (Accessed on July 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLindon LA, James G, Beckmann MM, et al. Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial. Hum Reprod 2023; 38:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coomarasamy A, Dhillon-Smith RK, Papadopoulou A, et al. Recurrent miscarriage: evidence to accelerate action. Lancet 2021; 397:1675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise J. NICE recommends progesterone to prevent early miscarriage. BMJ 2021; 375:n2896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devall AJ, Papadopoulou A, Podesek M, et al. Progestogens for preventing miscarriage: a network meta-analysis. Cochrane Database Syst Rev 2021; 4:CD013792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coomarasamy A, Williams H, Truchanowicz E, et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med 2015; 373:2141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coomarasamy A, Devall AJ, Cheed V, et al. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. N Engl J Med 2019; 380:1815.
          </a>
         </li>
         <li class="breakAll">
          Ectopic pregnancy and miscarriage: diagnosis and initial management, National Institute for Health and Care Excellence (NICE), London 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi BC, Polgar K, Xiao L, Hill JA. Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 2000; 15 Suppl 1:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mumford SL, Silver RM, Sjaarda LA, et al. Expanded findings from a randomized controlled trial of preconception low-dose aspirin and pregnancy loss. Hum Reprod 2016; 31:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blomqvist L, Hellgren M, Strandell A. Acetylsalicylic acid does not prevent first-trimester unexplained recurrent pregnancy loss: A randomized controlled trial. Acta Obstet Gynecol Scand 2018; 97:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010; 115:4162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan X, Wang D, Yan P, Li H. Low molecular weight heparin or LMWH plus aspirin in the treatment of unexplained recurrent miscarriage with negative antiphospholipid antibodies: A meta-analysis of randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2022; 268:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naimi AI, Perkins NJ, Sjaarda LA, et al. The Effect of Preconception-Initiated Low-Dose Aspirin on Human Chorionic Gonadotropin-Detected Pregnancy, Pregnancy Loss, and Live Birth : Per Protocol Analysis of a Randomized Trial. Ann Intern Med 2021; 174:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquier E, de Saint Martin L, Bohec C, et al. Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood 2015; 125:2200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schleussner E, Kamin G, Seliger G, et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med 2015; 162:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 2014; 384:1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quenby S, Booth K, Hiller L, et al. Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial. Lancet 2023; 402:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott JR, Pattison N. Human chorionic gonadotrophin for recurrent miscarriage. Cochrane Database Syst Rev 2000; :CD000101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohnet HG, Kato K, Trapp M, et al. Different hormonal patterns in human menopausal gonadotropin-treated, clomiphene citrate-treated, and untreated conception cycles. Fertil Steril 1986; 45:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray DL, Reich L, Adashi EY. Oral clomiphene citrate and vaginal progesterone suppositories in the treatment of luteal phase dysfunction: a comparative study. Fertil Steril 1989; 51:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark DA, Coulam CB, Stricker RB. Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J Assist Reprod Genet 2006; 23:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egerup P, Lindschou J, Gluud C, et al. The Effects of Intravenous Immunoglobulins in Women with Recurrent Miscarriages: A Systematic Review of Randomised Trials with Meta-Analyses and Trial Sequential Analyses Including Individual Patient Data. PLoS One 2015; 10:e0141588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tewary S, Lucas ES, Fujihara R, et al. Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells: A randomised, double-blind placebo-controlled feasibility trial. EBioMedicine 2020; 51:102597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas ES, Dyer NP, Murakami K, et al. Loss of Endometrial Plasticity in Recurrent Pregnancy Loss. Stem Cells 2016; 34:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brighton PJ, Maruyama Y, Fishwick K, et al. Clearance of senescent decidual cells by uterine natural killer cells in cycling human endometrium. Elife 2017; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarpellini F, Klinger FG, Rossi G, Sbracia M. Immunohistochemical Study on the Expression of G-CSF, G-CSFR, VEGF, VEGFR-1, Foxp3 in First Trimester Trophoblast of Recurrent Pregnancy Loss in Pregnancies Treated with G-CSF and Controls. Int J Mol Sci 2019; 21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tempfer CB, Kurz C, Bentz EK, et al. A combination treatment of prednisone, aspirin, folate, and progesterone in women with idiopathic recurrent miscarriage: a matched-pair study. Fertil Steril 2006; 86:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lund M, Kamper-Jørgensen M, Nielsen HS, et al. Prognosis for live birth in women with recurrent miscarriage: what is the best measure of success? Obstet Gynecol 2012; 119:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999; 14:2868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bricker L, Farquharson RG. Types of pregnancy loss in recurrent miscarriage: implications for research and clinical practice. Hum Reprod 2002; 17:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg RL, Mayberry SK, Copper RL, et al. Pregnancy outcome following a second-trimester loss. Obstet Gynecol 1993; 81:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edlow AG, Srinivas SK, Elovitz MA. Second-trimester loss and subsequent pregnancy outcomes: What is the real risk? Am J Obstet Gynecol 2007; 197:581.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu CQ, Nichols K, Carwana M, et al. Preterm birth after recurrent pregnancy loss: a systematic review and meta-analysis. Fertil Steril 2022; 117:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Field K, Murphy DJ. Perinatal outcomes in a subsequent pregnancy among women who have experienced recurrent miscarriage: a retrospective cohort study. Hum Reprod 2015; 30:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jivraj S, Anstie B, Cheong YC, et al. Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study. Hum Reprod 2001; 16:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Facca TA, Mastroianni-Kirsztajn G, Sabino ARP, et al. Pregnancy as an early stress test for cardiovascular and kidney disease diagnosis. Pregnancy Hypertens 2018; 12:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carbillon L. Pregnancy is an essential spontaneous screening stress test for the risk of early stroke in women. Stroke 2008; 39:e138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang C, Chung HF, Dobson AJ, et al. Infertility, recurrent pregnancy loss, and risk of stroke: pooled analysis of individual patient data of 618 851 women. BMJ 2022; 377:e070603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang YX, Mínguez-Alarcón L, Gaskins AJ, et al. Association of spontaneous abortion with all cause and cause specific premature mortality: prospective cohort study. BMJ 2021; 372:n530.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5444 Version 65.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6604890" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Etiology of recurrent pregnancy losses and outcome of subsequent pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9070732" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Future pregnancy outcome in unexplained recurrent first trimester miscarriage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15959648" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Genetic evaluation and counseling of couples with recurrent miscarriage: recommendations of the National Society of Genetic Counselors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12137856" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Preimplantation genetic diagnosis for advanced maternal age and other indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12909520" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Preimplantation genetic diagnosis as both a therapeutic and diagnostic tool in assisted reproductive technology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17169213" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Preimplantation genetic diagnosis significantly improves the pregnancy outcome of translocation carriers with a history of recurrent miscarriage and unsuccessful pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17611204" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : In vitro fertilization with preimplantation genetic screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7113692" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Reproductive performance of women with uterine anomalies. An evaluation of 182 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284765" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The diagnosis and reproductive outcome after surgical treatment of the complete septate uterus, duplicated cervix and vaginal septum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18571168" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hysteroscopic resection of the septum improves the pregnancy rate of women with unexplained infertility: a prospective controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20864409" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Septate, subseptate and arcuate uterus decrease pregnancy and live birth rates in IVF/ICSI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9777621" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Recurrent pregnancy loss. An update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9253317" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Thyroiditis after pregnancy loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31407629" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Thyroid Peroxidase Antibodies and Prospective Live Birth Rate: A Cohort Study of Women with Recurrent Pregnancy Loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16621910" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9696215" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12407039" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25331518" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Immunotherapy for recurrent miscarriage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17166218" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25412569" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11172853" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Use of human menopausal gonadotropins in the treatment of endometrial defects associated with recurrent miscarriage: preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31486805" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : ESHRE guideline: recurrent pregnancy loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27278003" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Intent to treat analysis of in vitro fertilization and preimplantation genetic screening versus expectant management in patients with recurrent pregnancy loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7424911" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A cytogenetic study of repeated spontaneous abortions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8921088" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Oocyte donation in women with recurrent pregnancy loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33827766" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Diagnosis and treatment of luteal phase deficiency: a committee opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33827766" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Diagnosis and treatment of luteal phase deficiency: a committee opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36806843" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33915096" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Recurrent miscarriage: evidence to accelerate action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34819313" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : NICE recommends progesterone to prevent early miscarriage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33872382" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Progestogens for preventing miscarriage: a network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26605928" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A Randomized Trial of Progesterone in Women with Recurrent Miscarriages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31067371" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31067371" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10928418" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26759138" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Expanded findings from a randomized controlled trial of preconception low-dose aspirin and pregnancy loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29972884" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Acetylsalicylic acid does not prevent first-trimester unexplained recurrent pregnancy loss: A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20335572" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Aspirin plus heparin or aspirin alone in women with recurrent miscarriage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20237316" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34794071" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Low molecular weight heparin or LMWH plus aspirin in the treatment of unexplained recurrent miscarriage with negative antiphospholipid antibodies: A meta-analysis of randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33493011" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The Effect of Preconception-Initiated Low-Dose Aspirin on Human Chorionic Gonadotropin-Detected Pregnancy, Pregnancy Loss, and Live Birth : Per Protocol Analysis of a Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25636341" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25938990" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25066248" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37271152" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796127" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Human chorionic gonadotrophin for recurrent miscarriage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2937655" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Different hormonal patterns in human menopausal gonadotropin-treated, clomiphene citrate-treated, and untreated conception cycles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2910717" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Oral clomiphene citrate and vaginal progesterone suppositories in the treatment of luteal phase dysfunction: a comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16421767" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26517123" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The Effects of Intravenous Immunoglobulins in Women with Recurrent Miscarriages: A Systematic Review of Randomised Trials with Meta-Analyses and Trial Sequential Analyses Including Individual Patient Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31928963" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells: A randomised, double-blind placebo-controlled feasibility trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26418742" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Loss of Endometrial Plasticity in Recurrent Pregnancy Loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29227245" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Clearance of senescent decidual cells by uterine natural killer cells in cycling human endometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31906232" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Immunohistochemical Study on the Expression of G-CSF, G-CSFR, VEGF, VEGFR-1, Foxp3 in First Trimester Trophoblast of Recurrent Pregnancy Loss in Pregnancies Treated with G-CSF and Controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16716321" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A combination treatment of prednisone, aspirin, folate, and progesterone in women with idiopathic recurrent miscarriage: a matched-pair study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22183209" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prognosis for live birth in women with recurrent miscarriage: what is the best measure of success?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10548638" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11980763" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Types of pregnancy loss in recurrent miscarriage: implications for research and clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8437803" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Pregnancy outcome following a second-trimester loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18060941" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Second-trimester loss and subsequent pregnancy outcomes: What is the real risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35131102" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Preterm birth after recurrent pregnancy loss: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25759495" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Perinatal outcomes in a subsequent pregnancy among women who have experienced recurrent miscarriage: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11139545" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29198741" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Pregnancy as an early stress test for cardiovascular and kidney disease diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18583559" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Pregnancy is an essential spontaneous screening stress test for the risk of early stroke in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732311" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Infertility, recurrent pregnancy loss, and risk of stroke: pooled analysis of individual patient data of 618 851 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33762255" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Association of spontaneous abortion with all cause and cause specific premature mortality: prospective cohort study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
